Interestingly, additional activating mutations in BRAF that circumvent pharmacologic inhibition were not observed, contrasting with observations on targeted therapies in other cancers and suggesting that additional BRAF mutations are either harder to acquire under treatment pressure or unable to prevent inhibitor binding. This evidence concerns the gene BRAF and cancer.